London's Exogenous Surfactant Study for COVID19

• Status: Completed
• Trial end date: 2021-10-06
• Target enrollment: 0
• Participant gender: All

Summary

The research team is investigating administering exogenous surfactant in COVID-19 patients with ARDS. The overall goal is to improve the outcome (mortality) of mechanically ventilated COVID-19 patients. Although the investigators anticipate that clinical outcomes may improve in the small group of patients receiving exogenous surfactant therapy in this small, single center study, the primary goal is to first determine feasibility and safety.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Lawson Health Research Institute
• Collaborator: London Health Sciences Centre
• Treatments: Pulmonary Surfactants

Criteria

Inclusion Criteria:

1. age over 18 years

2. definitive proof of COVID-19 infection within 48 hours of intubation

3. acute respiratory failure with PaO2/FiO2 < 300 requiring intubation

Exclusion Criteria:

1. known or high suspicion of pre-existing heart failure, unstable angina

2. presence of severe shock with hemodynamic instability despite escalating vasopressors

3. severe, underlying lung disease (COPD, pulmonary fibrosis, lung cancer. etc.)

4. Concurrent treatments are delivered directly into the lung (ie anesthetics etc)

5. Diagnosis of pulmonary hemorrhage